On April 27, 2019, the SEC filed a complaint in the United States District Court for the Southern District of New York against AbbVie, Inc. ("AbbVie"), alleging that AbbVie violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The complaint alleges that AbbVie violated Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and that AbbVie violated Rule 10b-5 thereunder.  In a parallel action, the U.S. Attorney's Office for the Southern District of New York today announced criminal charges against AbbVie.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, charges AbbVie with violating Section 17(a) of the Securities Act, Section 10(b) of the Exchange Act, Rule 10b-5 thereunder, and Sections 206(1), 206(2), and 206(4) of the Investment Advisers Act of 1940 ("Advisers Act") and Rule 206(4)-8 thereunder.  The complaint also charges AbbVie with violating Section 10(b) of the Exchange Act.  The SEC's complaint charges AbbVie with violating Sections 206(1) and 206(2) of the Investment Advisers Act and Rule 206(4)-8 thereunder, and seeks permanent injunctions, disgorgement of ill-gotten gains with prejudgment interest, and civil penalties.  The SEC's investigation, which is continuing, is being conducted by Terence Flynn and Amy Gwiazda of the Boston Regional Office.  The litigation will be led by Mr. Flynn and Ms. Gwiazda.  The SEC appreciates the assistance of the Financial Industry Regulatory Authority.